B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5 þ B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fused anti-CD20 single-chain variable fragment (scFv) is used in combination with biotinylated MHC class I molecules containing CMV pp65 peptide (HLA/CMV). We demonstrate that B-CLL cells coated with this CD20-HLA/CMV complex can be lysed by autologous CMV-specific CTL with similar efficiency as B-CLL cells directly loaded with CMV peptide. Killing is HLA restricted and occurs at scFv CD20 concentrations of X100 ng ml À1 and HLA/CMV concentrations of X20 ng ml
Introduction
At present, there is no curative treatment for B-cell chronic lymphocytic leukaemia (B-CLL). The slow progression and rather long median survival make B-CLL an attractive target for immunotherapy. For adequate T-cell-mediated cancer immunotherapy, it is necessary to induce activation and differentiation of tumour-specific T cells. However, in B-CLL (like in many other types of cancer), this is severely hampered by the poor antigen-presenting capacity of the malignant B cells, which express low levels of co-stimulatory molecules and therefore escape immune surveillance. Furthermore, there is evidence that B-CLL is accompanied by T-cell dysfunction. 1, 2 Nevertheless, CD40 stimulation of B-CLL cells was found to enhance costimulatory capacity of the tumour cells 3 and it has been demonstrated that not only allogenic 4, 5 but also autologous 6 B-CLL-directed T cells can be generated in vitro. Moreover, in a phase I clinical trial, autologous, ex vivo CD40L-transduced B-CLL cells induced a reduction of the tumour mass upon reinfusion. 7 Although the specific antigen remains elusive, these studies show that active immunization against B-CLL is possible. A disadvantage, however, of the discussed strategies is the need for complex ex vivo treatment of tumour cells.
We have previously shown that in patients with B-CLL, considerably expanded numbers of cytomegalovirus (CMV)-reactive CD8 þ T cells are present. 8 Cytomegalovirus-specific CD8 þ T cells in a latent stage of the infection possess an effector phenotype, with high contents of perforin and granzymes. 9 This contrasts with the CD8 þ T-cell pool against viruses that are cleared by the immune system, like influenza and respiratory syncytial virus. 10 Recently, we have demonstrated that these CMV-specific CD8 þ cells are potent cytotoxic effector cells when directed against B-CLL cells loaded with CMV peptide. 11 Importantly, these CD8 þ cells do not require ex vivo (re)stimulation but display their cytotoxicity directly after isolation from peripheral blood. 11 These data demonstrate the potential to redirect autologous CMV-specific cytotoxic T cells (CTLs) towards B-CLL cells for cancer immunotherapy.
To develop this approach towards applications in vivo, we investigated the possibility to deliver CMV peptides specifically to B-CLL cells via antibody-targeted HLA class I/peptide complexes in an in vitro study. We have used a targeted complex (TC) consisting of a streptavidin (SA)-fused anti-human CD20 single-chain variable fragment (B9E9 scFv) coupled to CMV-peptide-loaded biotinylated HLA class I. 12 We compared B-CLL coated with these TC with B-CLL directly loaded with CMV peptide with respect to efficacy and specificity of autologous T-cell-mediated killing. Moreover, we analysed the capacity to induce proliferation and cytokine production by CMV-specific T cells.
Materials and methods

Patient samples
After obtaining informed consent, 30 ml of blood was drawn from patients fulfilling the diagnostic criteria for B-CLL. 13 All patients had Rai clinical stage 0-II and had not received prior treatment. Peripheral blood mononuclear cells (PBMCs) obtained via density gradient centrifugation, were directly frozen in fetal calf serum (FCS) containing 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO) and were stored in liquid nitrogen before use. 8 B-cell chronic lymphocytic leukaemia PMBC fractions contained 490% of CD5 þ CD19 þ B cells as assessed by flowcytometry. On the day of use, cells were thawed and cultured in Iscove's modified essential medium (IMDM) supplemented with 10% heat-inactivated FCS, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. B cells were obtained from a PBMC fraction of a healthy donor by depletion of T cells, monocytes and macrophages, 14 using anti-CD3, anti-CD14 and anti-CD16 immunomagnetic beads and a magnetic particle concentrator (both Dynal AS, Oslo, Norway).
Reagents
HLA-A2-binding NLVPMVATV CMVpp65 peptide and HLA-B7-binding TPRVTGGGAM CMVpp65 peptide (IHB-LUMC peptide synthesis library facility, Leiden, The Netherlands) were used. The B9E9 scFvSA fusion protein, consisting of the variable region of murine IgG2a anti-human CD20 fused to SA (scFv CD20) has been described before 12 and was used in combination with biotinylated human MHC class I molecules containing CMVpp65 peptide (HLA/CMV). In these experiments, CMVpp65 peptide containing MHC class I molecules HLA-A*0201/ NLVPMVATV (HLA-A2) and HLA-B*0702/TPRVTGGGAM (HLA-B7), generated by ProImmune (Oxford, UK), was used. Complexes, formed by scFvSA and HLA/CMV, are hereafter referred to as targeted constructs (TC).
Expansion of virus-specific autologous CTL
Thawed PBMCs (490% CLL cells) from CMV-seropositive B-CLL patients were used for expansion of CMV-specific CTL as described before. 11 Briefly, PBMCs (at a final concentration of 5 Â 10 6 cells ml À1 ) were stimulated with CMVpp65 peptide (1.25 mg ml À1 )-loaded B-CLL cells and IL-2 (50 U ml
À1
; Biotest Ag, Dreieich, Germany). After 1 week, cells were restimulated on a weekly basis with CMV peptide-loaded irradiated (30 Gy) EBV-transformed cell-lines expressing either HLA-A2 or HLA-B7 (5 Â 10 4 cells ml À1 ) in the presence of IL-2. Percentage of CMVspecific CTL in culture was determined by fluorescenceactivated cell sorting (FACS) analysis after staining cell culture samples with CD8-PE (Becton Dickinson, San Jose, CA,USA) and APC-conjugated A2 or B7 CMV tetramers (Sanquin, Amsterdam, The Netherlands).
Cytotoxicity assay
Cytotoxic T lymphocytes activity was measured in a standard 51 Cr release assay. 15 As targets, freshly thawed B-CLL cells and B cells were used. Target cells were labelled with 50 ml 51 Cr (30 mg ml À1 , 500 mCi mg À1 ; Amersham, Buckinghamshire, England). After washing, cells were incubated at 371C either with 0.1 mg ml À1 CMVpp65 for 1 h or with scFv CD20 (50 mg ml À1 ) for 30 min and, subsequently, with HLA/CMV (at various concentrations) for 20 min. Autologous CMV-specific effector cells (obtained as described above) were incubated with 3000 51 Cr-labelled target cells at a 4:1 effector:target ratio. After 4 h, released radioactivity was measured and specific lysis was calculated according to the following formula: percentage of specific release ¼ ((experimental release-spontaneous release)/ (maximum release-spontaneous release)) Â 100%. Results are presented as specific lysis and represent the median of specific lysis in six replicate samples7s.e.m.
In vitro stability assay HLA class I-negative Daudi cells were targeted with TC as described before. 16 Briefly, Daudi cells were incubated with scFv CD20 at 50 mg ml À1 for 30 min and, after washing, with HLA/CMV complexes at 2.5 mg ml À1 for another 20 min. After labelling, cells were washed and resuspended in medium and grown at 371C in a 5% CO 2 -containing atmosphere. At various time points, samples of cells were taken, washed, stained with a fluorescein isothiocyanate (FITC)-labelled anti-HLA class I antibody (PharMingen, San Diego, CA,USA) and analysed by flowcytometry.
Furthermore, HLA-A2-negative B-CLL cells were targeted with HLA-A2 TC. B-cell chronic lymphocytic leukaemia cells were incubated with scFv CD20 at 50 mg ml À1 for 30 min and, after a washing step, with HLA/CMV complexes at 2.5 mg ml À1 for another 20 min. After labelling, cells were washed and resuspended in medium and grown at 371C in a 5% CO 2 -containing atmosphere. Immediately after labelling and after 24 h, samples were taken, washed, stained with a FITC labelled anti-HLA-A2 antibody (PharMingen, San Diego, CA,USA) and analysed by flowcytometry. Furthermore, TC-coated B-CLL (t ¼ 24 h) and untreated B-CLL cells from the same donor (t ¼ 24 h) were used as targets in a standard 51 Cr release assay with CMV-specific HLA-A2 CTL as effector cells at a 1:1 effector:target ratio.
TC-induced proliferation of CMV-specific CTL
Freshly thawed PBMCs from CMV-seropositive B-CLL patients were labelled with carboxy fluorescein diacetate succinimidyl ester (CFSE) (Molecular Probes, Eugene, OR,USA). After washing, cells were incubated with scFv CD20 (50 mg ml À1 ) and subsequently with HLA/CMV (500 ng ml À1 ). The labelled cells were then cultured in medium at 371C. On day 7, samples were taken from the cell cultures and stained with CD8PE-and APCconjugated CMV tetramers.
Cytokine production assays
CMV-specific effector cells were stimulated for 6 h at 371C with TC-coated B-CLL. 17, 18 All stimulations were performed in medium containing 4 mg ml À1 anti-CD28 (15E8) and 2 mg ml anti-CD29 (TS2/16). For the last 5 h of culture, brefeldin A (Sigma-Aldrich, St Louis, MO) was added in a final concentration of 10 mg ml À1 . After culture, the cells were fixed in FACS lysing solution (BD Biosciences, San Jose, CA) and permeabilized (BD Biosciences). On those cells, an intercellular staining was performed using anti-interferon (IFN-g)-FITC, anti-tumour necrosis factor (TNF-a)-FITC and anti-MIP-1b-PE (all from BD Biosciences). To discriminate CTL from B-CLL, anti-CD8 PerCP Cy5.5 (BD Biosciences) was used, whereas anti-C69 APC (BD Biosciences) staining was applied to visualize activated cells.
In order to analyse the cytotoxic capacity of cytokine producing CMV-specific CD8 cells, CMV-specific effector cells were stimulated with TC-coated or CMVpp65-treated B-CLL cells as described above. To isolate the IFN-g-secreting cells, they were labelled using an IFN-g capture assay as described before. 19 Briefly, the cells were washed in ice-cold buffer (phosphate buffered saline containing 0.5% bovine serum albumin and 2 mM ethylene diamine tetraacetic acid) and resuspended in ice-cold medium. Next, IFN-g capture reagent was added (Miltenyi Biotech, Bergisch Gladbach, Germany) and the cells were put on ice for 5 min. Then, warm culture medium was added and the cells were incubated at 371C for 45 min under slow continuous rotation. After incubation, icecold buffer was added and the cells were spinned down. Subsequently, the pellet was resuspended in ice-cold buffer. PE-conjugated IFN-g detection antibody (Miltenyi Biotech) and FITC-conjugated antibodies against CD4, CD14, CD16 and CD19 (all BD Biosciences) were added and the cells were incubated on ice for another 10 min. After washing with ice-cold buffer, the cells were resuspended in RPMI containing 5% FCS. CD4/14/16/19-negative IFN-g-positive cells were sorted by flowcytometry (FACS Aria, BD Biosciences) and then collected. The sorted cells were cultured for 4 days (in the presence of IL-2) and subsequently used as effector cells in a standard chromium release assay at a 1:1 effector:target ratio.
Results
Lysis of HLA/CMV-targeted B-CLL by CMV-specific CTL
We tested the efficacy of in vitro-expanded CMV-specific CTL in a standard 4 h chromium release assay against autologous B-CLL cells either loaded with CMVpp65 or targeted with TC formed by scFv CD20 and HLA/CMV. Using a 50 mg ml À1 concentration of scFv CD20 and varying concentrations of HLA/CMV, targeted B-CLL cells were lysed. When diluting the HLA/CMV reagent, lysis of targeted B-CLL became suboptimal at concentrations p4 ng ml À1 (Figure 1a ), whereas lysis of CMVpp65-loaded B-CLL was not efficient at concentrations p100 pg ml À1 (data not shown). In view of the molecular weight of both constructs (HLA/CMV Mw ¼ 45 kDa; CMVpp65 Mw ¼ 1 kDa) at a molar base 100 pg ml À1 of CMVpp65 is comparable to 4.5 ng ml Next, scFv CD20 concentrations were varied (using a constant HLA/CMV concentration of 100 ng ml À1 ). Lysis was limited below concentrations of 100 ng ml À1 (Figure 1b ). Molecular weights of scFv CD20 and HLA/CMV are equal ( ¼ 45 kDa). Single-chain variable fragment CD20 can bind a maximum number of four biotinylated HLA molecules, thereby forming tetramers. As lysis remains efficient at equal scFv CD20 and HLA/CMV concentrations (both 100 ng ml À1 ), this suggests that even in a monomer form, TC facilitate killing of the targeted cells.
To test whether the TC behave as genuine peptide presenting MHC molecules, B-CLL cells from an HLA-A2 patient were coated with either A2-TC or B7-TC. B7-TC-coated HLA-A2 B-CLL cells were lysed by CMV-specific HLA-B7 CTL to a comparable extent as B7-TC-coated autologous (HLA-B7) B-CLL. In contrast, A2-TC-coated HLA-A2 B-CLL were unaffected by CMV-specific HLA-B7 CTL (Figure 1c) . Importantly, autologous, non-CMV-specific CD8 þ T cells (containing only 1.76% CMV-specific CTL) did not induce lysis of TC-coated B-CLL (Figure 1c) . Therefore, it can be concluded that there is a restriction to lysis determined by the HLA type of the TC and the antigen specificity of the CTL, indicating that MHC/peptide-TCR interactions trigger CTL activity similar to autologous MHC molecules.
The effect of CD20 surface expression on TC-induced lysis B-CLL cells have a low surface expression of CD20 as compared to normal B cells. 20 To test the effect of CD20 surface expression on susceptibility to TC-mediated lysis, B-CLL cells (CD20 expression: mean fluorescence intensity (MFI) ¼ 88), normal B cells (MFI ¼ 770) and B-CLL cells with (unusually) high CD20 surface expression (CD20 high ; MFI ¼ 538) were coated with TC using varying HLA/CMV concentrations. Only at HLA/CMV concentrations below 4 ng ml À1 , the lysis of TC-coated B-CLL by CMV-specific CTL was impaired, whereas the lysis of normal B cells and CD20 high B-CLL remained unaffected (Figure 2) . Therefore, the 10-fold lower CD20 expression on B-CLL does not prevent efficient lysis by TC. ). The right hand bar represents activity of non-CMV-specific autologous T cells against TC-coated B-CLL. CTL, cytotoxic T lymphocytes; CMV, cytomegalovirus; B-CLL, B-cell chronic lymphocytic leukaemia; TC, targeted complex; scFv, single chain variable fragment.
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In vitro stability of TC
To evaluate the stability of the cell-bound TC in time, we targeted (HLA class I-negative) Daudi cells with TC. The presence of the TC on the cells was detected using a broad reacting anti-HLA class I antibody and FACS analysis (Figure 3a) . Targeted complex appeared to be stable for at least 24 h when targeted to Daudi cells.
To analyse the stability of TC on CLL cells, we targeted HLA-A2-negative B-CLL cells with HLA-A2 TC, and used these cells after 24 h as targets in a standard chromium release assay. The presence of TC on the cells was detected with an anti-HLA-A2 antibody and FACS analysis. At 24 h after targeting, the presence of the TC on B-CLL as detected by FACS analysis was severely reduced (data not shown). However, these cells were still lysed effectively by CMV-specific HLA-A2 CTL (Figure 3b) . Thus, apparently 24 h after binding of TC, there still is a sufficient amount present on B-CLL to induce lysis.
TC proliferation and cytokine production of CMV-specific CTL
In order to activate the immune system in vivo, CMV-specific CTL must be capable of proliferation and production of cytokines upon antigen encounter. We tested both capacities in an in vitro setting. To track antigen-specific proliferation, we labelled a PBMC fraction of a B-CLL patient which contained CMV-specific CTL (0.32% of total lymphocytes) first with CFSE and, subsequently, with a combination of scFv CD20 (50 mg ml À1 ) and HLA/CMV (500 ng ml À1 ). After labelling, the cells were incubated for 7 days in the presence of IL-2 (50 U ml À1 ). Proliferation of CMV-specific CTL was measured by analysing the percentage of CD8 þ /tetramer þ cells in the lymphocyte population. Within the CD8 þ /tetramer þ fraction, we measured the intensity of the CFSE signal (Figure 4) . Whereas non-CMV-labelled PBMC showed no increase in CMV-specific CTL, an increased percentage of CMV-specific CTL was observed in the HLA/CMV-labelled PMBC fraction (6.0% of total lymphocytes), which was accompanied by a decrease in CFSE signal intensity in most cells (indicating proliferation has occurred). ). On day 7, the percentage of CMV-specific CTL in the total lymphocyte population was determined by CD8 and CMV tetramer double staining. Before start of the assay, PBMC were labelled with CFSE to track cell division within the CMV-specific CTL population (as depicted in the lower panel of the figure). CMV, cytomegalovirus; CTL, cytotoxic T lymphocytes; PBMCs, peripheral blood mononuclear cells; B-CLL, B-cell chronic lymphocytic leukaemia; TC targeted complex; CFSE, carboxy fluoresceindiacetate succinimidyl ester.
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Furthermore, we measured the production of several cytokines by CMV-specific CD8 cells upon 6 h of stimulation with TC-coated B-CLL. TC-coated B-CLL induced activation of CMVspecific CD8 cells (as indicated by CD69 upregulation) resulting in production of IFN-g, TNF-a and macrophage inflammatory protein (MIP-1b) (Figure 5a ). Next, we wanted to confirm that these cytokine-producing cells are indeed the same cells that can induce lysis of those TC-coated cells. To this end, we stimulated CMV-specific CTL with either TC-or CMVpp65-coated B-CLL. Subsequently, we labelled IFN-g -producing cells with an IFN-g detection kit and sorted them (Figure 5b) . Four days later, we tested the capacity of those cells to lyse CMVpp65-loaded B-CLL. We noticed that both TC-and CMVpp65-prestimulated IFN-g-secreting cells were able to induce lysis of both CMVpp65-loaded or TC-coated B-CLL (Figure 5c ). Thus, the TC are capable of inducing immune activation as assessed by proliferation and cytokine production by CMV-specific CTL.
Discussion
In the present study, we have shown that B-CLL cells, targeted with complexes consisting of a SA-fused anti-human CD20 scFv coupled to CMV-peptide-loaded biotinylated HLA class I molecules (TC), can be lysed by autologous CMV-specific CTL with efficiency similar to that of B-CLL cells directly loaded with CMV peptide. Furthermore, we have demonstrated that TC-coated B-CLL induce both proliferation and cytokine production (IFN-g, TNF-a, and MIP-1b) in CMV-specific CD8 þ T cells.
Most active immunotherapies require knowledge of the eliciting antigen and ex vivo manipulation of patient cells. The first aspect can be circumvented by applying the resident anti-CMV immunity. The second aspect was addressed in previous research by Savage et al., where the powerful effector mechanisms of virus-specific cytotoxic T cells were successfully linked with the specificity of monoclonal antibodies. In vitro experiments with CD20-expressing tumour cells and influenza or EBV-derived viral peptides, showed that CD20-targeted HLA class I/peptide complexes were expressed on the cultured tumour cells, and that these targeted tumour cells could be lysed very efficiently by PBMCs from healthy donors, in vitro prestimulated with viral antigen. 16 In vivo studies with severe combined immunodeficient (SCID) mice xenografted with the human B-cell lymphoma Daudi line showed adequate protection from tumour growth when HLA-A2/influenza peptide-targeted lymphoma cells were inoculated together with influenza-specific CTL. 21 Whether these findings can be extrapolated to a clinical situation is highly dependent on the penetration of the reagent in tissues. This aspect was addressed by Lev et al., 22 who demonstrated the efficacy of an scFv (anti-CD25 or anti-mesothelin)/HLA-A2 chimerical fusion protein in nude mice bearing pre-established human tumour xenografts. It could be argued that one-step targeting by such a (B65 kDa) reagent enables higher tissue penetration compared to the two-step approach described here. However, in a recent phase I study in B-cell non-Hodgkin lymphoma patients, the SA CD20 scFv fragment in combination with biotinylated 99 Yttrium showed adequate penetration in lymph nodes, subcutaneous localizations, joints and even testes. 23 As the molecular weight of biotinylated HLA/ CMV is similar (B45 kDa), it is expected that the penetration of HLA/CMV will be comparable. Although a one-step approach avoids the exposure of (potentially immunogenic) Novel bridging reagent for active immunotherapy in CLL R Mous et al SA, a two-step labelling procedure enables higher flexibility for patients with different HLA types. Our data on T-cell proliferation and cytokine production induced by TC-coated B-CLL are in line with a recent study showing that human immunodeficiency virus (HIV) and Karposi sarcoma antigen-containing HLA complexes induce expansion and activation of autologous HIV and Karposi sarcoma-specific CTL. 24 This emphasizes the potential of antibody-targeted MHC complexes as a new approach for therapeutic vaccination. In our study, intracellular staining revealed antigen-triggered production of IFN-g, TNF-a and MIP-1b in CD8-positive T cells. Interferon-g is known to recruit T cells, activate macrophages and induce upregulation of MHC class I and II. 25 Tumour necrosis factor-a also activates macrophages. 26 Finally, MIP-1b is a cytokine, which is thought to be involved in the activation of monocytes, macrophages and, importantly, dendritic cells (DC). 27 This activation of macrophages and DC may facilitate the uptake and presentation of tumour cell particles. In vitro, it has been shown that offering apoptotic bodies of B-CLL cells to DC can induce autologous tumour-specific CTL. 6 Thus, in B-CLL, the CD20-HLA/CMV complexes might be a doubleedged sword: direct induction of both T-cell-mediated killing and a secondary activation of B-CLL-specific T-cell-mediated immune response.
Cytomegalovirus-specific CD8 þ cells are excellent effector cells for possible use in clinical cellular immunotherapy studies. They are proven to be cytotoxic, but not autoreactive and capable of homing in a broad variety of tissues. The approach is widely applicable because 70-90% of healthy adults are CMV positive. In our recent study, 72% of B-CLL patients were found to be CMV-seropositive. 8 It has to be noted that the latter figure might be a slight underestimation of the real proportion of CMVpositive patients because hypogammaglobulinaemia is frequently present in (advanced) B-CLL.
Especially in B-CLL, there are a number of advantages of the presented approach over the use of (radiolabelled) CD20 antibodies. Monotherapy with conventional doses of rituximab, a human/mouse chimeric CD20 monoclonal antibody, has only limited efficacy. 28 This is probably owing to the low expression of CD20 in B-CLL precluding optimal complement activation. 29 Moreover, in contrast to many cell lines, freshly isolated B-CLL cells are resistant to CD20-mediated antibody-dependent cellular cytotoxicity (ADCC) by NK cells, an important second effector mechanism in vivo of CD20 monoclonal antibodies. 30 Radiolabelled CD20 antibodies have considerable side effects, notably myelosuppression and increased risk for secondary myelodysplasia or acute myeloid leukaemia. 31 However, unlike ADCC or complement-dependent cytotoxicity, T-cell activation and killing requires only a few TCRs to drive the process. Notably, virus-specific CTL require only minute amounts of peptide presented on target cells. The potency of CMV-specific CTL is emphasized by the findings that the 10-fold lower CD20 surface expression on B-CLL compared to normal B cells hardly seems to affect the lysis of B-CLL (Figure 2) .
The findings of our study constitute a necessary step towards possible application of CD20-HLA/CMV complexes for immunotherapy of B-cell malignancies. The next step will be to test the CD20-HLA/CMV targeting complexes in vivo in a combined mouse B-cell tumour/CMV model. It is obvious that this recently recognized capacity to redirect existing antiviral immunity towards tumour cells has a utility in cancer immunotherapy far beyond CMV and B-CLL.
